Part of Thermo Fisher Scientific


COLLIBRI is a consortium that aims to accelerate progress in the field of inflammatory bowel disease through the use of protein biomarkers.

What are the main aims of COLLIBRI?

Collaboration: engage both academic and industrial partners to share both clinical samples and the data obtained from relevant studies.

A step change in data power: generate novel insights into disease pathogenesis and find novel biomarker signatures at the proteomic level.

The consortium looks to address questions of immediate interest to academia and industry, with existing Olink protein data in the first phase, but looking to generate additional new protein biomarker data in the future. Key elements in these collaborative projects will include phenotypic detail, consitency among partners in the definitions used, and robust information regarding sample storage and handling.

Key principles

  • Open and transparent communication of activities within the
    consortium and disclosure of closely related work outside of it.
  • Equal opportunities for contributions across participating members.
  • Equal access to the data.
  • Adherence to common practices for conference presentations and
  • Rapid response to requests for feedback.


If you are interested in joining COLLIBRI, or have any questions, don’t hesitate to get in touch with us at jonas.halfvarsson@regionorebrolan.se or bern.verstockt@kuleuven.be.

Follow COLLIBRI on X (Twitter) at @CollibriIbd

Governance principles

  • The organization will function in a democratic, transparent and coordinated way.
  • Regular meeting invites will be sent to all of the consortium members.

Consortium policies

  • Cohort PIs will retain all rights to their own data.
  • Participation may be terminated at any time, after which data will be removed within 4 weeks.
  • If a combined analysis progressed to a final version, and manuscript preparation is underway, the results will remain as are, but no future joint analysis will be conducted on that specific dataset.
  • Additional members may join the consortium. Any expansion will be need to be agreed on by the steering committee and may be agreed on project-by-project.
  • All members will need to agree to abide by the consortium agreement.

Data sharing and collaborations

Data sharing

Data protection officers are looking into a GDPR-approved format to safely and correctly store the data

Industrial collaborators

  • Although this consortium is steered and driven by academia, agreements with individual industrial partners will be considered on a project-by-project basis.
  • This may include, but is necessarily not restricted to, validation of findings from COLLIBRI in datasets/samples that have been obtained by industrial partners during clinical trials.

Projects and output

Important information regarding projects

  • Projects (using individual data or via early access to summary data) should be discussed and approved by the COLLIBRI steering group before analyses are initiated.
  • Proposals are to be submitted to the chair of the steering committee using the COLLIBRI study proposal template.
  • Potential conflicts with other manuscripts within COLLIBRI should be resolved by a COLLIBRI steering committee in the first instance.

Results from COLLIBRI projects

  • Summary statistics should be released to the COLLIBRI partners who contributed to a specific project as soon as it is completed.
  • Results from COLLIBRI analyses will be made publicly available in due course, through publications.
  • The consortium will strive to make the summary data available upon publication of a manuscript using an unrestricted repository. However, specific solutions such as storage of summary data on secure servers managed by a COLLIBRI PI, with restricted logins, may be considered whenever needed.

Regulations on publications & authorships

  • A publication will be developed (may be modified, based on the results).
  • Publications should be prepared and submitted as rapidly as possible after results have been reviewed and confirmed.
  • The ICMJE criteria for authorships will be followed:
    • substantial contributions to the concept or design; or the acquisition, analysis or interpretation of the data; AND
    • drafting the work or revising it critically for important intellectual content; AND
    • final approval of the version to be published; AND
    • agreement to be accountable for all aspects of the work